Bridge­Bio spins out on­col­o­gy unit with $200M in back­ing for RAS as­sets

Bridge­Bio, a biotech known for its mod­el of set­ting up sub­sidiaries to house its R&D pro­grams, is split­ting off its on­col­o­gy unit with $200 mil­lion in sup­port from 11 in­vestors.

Cor­morant As­set Man­age­ment, which backed Bridge­Bio as a start­up, led the fi­nanc­ing for the spin­out, which will be known as Bridge­Bio On­col­o­gy Ther­a­peu­tics, or BBOT. It was known in­side Bridge­Bio as TheRas, for its re­search in RAS mu­ta­tions, one of the most com­mon dri­vers of can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER